Company Overview - Anxu Bio focuses on the research, development, production, and sales of POCT reagents and instruments [1] - The company has been recognized as a "Zhejiang Province Intellectual Property Demonstration Enterprise" and a "National Intellectual Property Advantage Enterprise" [1] - As of 2024, Anxu Bio has obtained a total of 305 authorized patents, including 43 invention patents [1] Financial Performance - For Q1 2025, Anxu Bio reported a revenue of 115 million yuan, a year-on-year decrease of 10.90% [1] - The net profit for the same period was approximately 34.03 million yuan, reflecting a year-on-year decline of 51.52% [1] - The gross profit margin for the company stood at 42.32% [1] Market Position - Anxu Bio's current price-to-earnings (PE) ratio is 30.77, compared to the industry average of 49.12 and the industry median of 36.07 [2] - The company's total market capitalization is 4.805 billion yuan [1][2] - As of Q1 2025, six institutions hold shares in Anxu Bio, with a total holding of approximately 50.38 million shares valued at 1.998 billion yuan [1]

Company Overview - Anxu Bio focuses on the research, production, and sales of POCT reagents and instruments, and has been recognized as a "Zhejiang Province Intellectual Property Demonstration Enterprise" and a "National Intellectual Property Advantage Enterprise" [1] - As of March 31, 2025, Anxu Bio had 5,935 shareholders, a decrease of 278 from the previous period, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Financial Performance - For Q1 2025, Anxu Bio reported revenue of 115 million yuan, a year-on-year decrease of 10.90%, and a net profit of 34.03 million yuan, down 51.52% year-on-year, with a gross profit margin of 42.32% [1] Market Position - Anxu Bio's current rolling price-to-earnings (PE) ratio is 30.51, while the average PE ratio for the medical device industry is 49.10, and the industry median is 36.43, placing Anxu Bio at the 69th position in the industry ranking [1][2] - The company's total market capitalization is 4.763 billion yuan [1][2] Intellectual Property and Certifications - In 2024, Anxu Bio added 44 new authorized patents, including 13 invention patents, bringing the total to 305 authorized patents, of which 43 are invention patents [1] - The company has obtained multiple authoritative certifications, including EU CE certification, Canadian certification, and Australian certification, with a total of 1,580 certifications, including 606 new certifications in the latest period [1]

Core Viewpoint - The report indicates that Hangzhou Anxu Biotechnology Co., Ltd. has maintained a sound governance structure and effective internal controls during the continuous supervision period, with no violations in fundraising, related transactions, or operational status [1][5]. Group 1: Company Governance and Internal Control - The company’s articles of association and governance systems are complete and effectively executed [2]. - The board of directors, supervisors, and senior management fulfill their responsibilities as required [2]. - Internal control systems are effectively implemented [2]. Group 2: Information Disclosure - The company has fulfilled its information disclosure obligations accurately and completely, with no false records or misleading statements [2][5]. Group 3: Independence and Related Party Transactions - The company maintains independence in assets, personnel, finance, and business, with no violations regarding the occupation of company funds by related parties [3][4]. Group 4: Fundraising and Usage - The company has adhered to fundraising management regulations, with funds stored in dedicated accounts and no unauthorized changes in usage [3][4]. Group 5: Related Transactions and Investments - There are no violations regarding external guarantees, related transactions, or significant external investments during the supervision period [4][5]. Group 6: Operational Status - The company’s business model and structure have not undergone significant adverse changes, and its operational status remains normal [4][5]. Group 7: Compliance and Recommendations - The company is advised to continue improving its governance structure and ensure timely information disclosure while managing fundraising effectively [5].

民生证券股份有限公司 关于杭州安旭生物科技股份有限公司 2024 年度持续督导工作现场检查报告 根据《证券发行上市保荐业务管理办法》《上海证券交易所股票上市规则》 《上海证券交易所上市公司自律监管指引第 11 号——持续督导》等有关法律、 法规的规定，民生证券股份有限公司（以下简称"保荐机构"）作为杭州安旭 生物科技股份有限公司（以下简称"安旭生物"或"公司"）首次公开发行股 票并在科创板上市的保荐机构，对公司 2024 年度（以下简称"本持续督导 期"）的规范运作情况进行了现场检查，现就有关情况报告如下： 一、本次现场检查的基本情况 （一）保荐机构 民生证券股份有限公司 （二）保荐代表人 孙闽、朱仙掌 （三）现场检查时间 2025 年 5 月 19 日 （四）现场检查人员 朱仙掌 （五）现场检查内容 公司治理、内部控制，信息披露，独立性以及与控股股东、实际控制人及 其他关联方资金往来情况，募集资金使用，关联交易、对外担保、重大对外投 资，经营状况等。 （六）现场检查手段 1、查看公司主要生产经营场所，对公司相关人员进行访谈； 1 2、查阅本持续督导期间公司召开的历次三会文件； 3、查阅本持续督导期间公司的信 ...

证券代码：688075 证券简称：安旭生物 公告编号：2025-013 杭州安旭生物科技股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 5 月 22 日 （二） 股东大会召开的地点：浙江省杭州市莫干山路 1418-50 号 4 幢 5 楼大会 议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 44 | | --- | --- | | 普通股股东人数 | 44 | | 2、出席会议的股东所持有的表决权数量 | 99,699,361 | | 普通股股东所持有表决权数量 | 99,699,361 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 78.4522 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 78.4522 ...

上海市锦天城律师事务所 关于杭州安旭生物科技股份有限公司 2024 年年度股东大会的 法律意见书 锦 天 城 律师事务 所 ALLBRIGHT LAW OFFICES 地址：上海市浦东新区银城中路 501 号上海中心大厦 9/11/12 层 传真: 021-20511999 电话: 021-20511000 邮编: 200120 上海市锦天城律师事务所 法律意见书 上海市锦天城律师事务所 一、 本次股东大会召集人资格及召集、召开的程序 经核查,公司本次股东大会由公司董事会召集召开。公司已于 2025年 4 月 30 日在上海证券交易所网站(http://www.sse.com.cn)和《上海证券报》和《证 券日报》上刊登《杭州安旭生物科技股份有限公司关于召开 2024年年度股东大 会的通知》,将本次股东大会的召开时间、地点、审议事项、出席会议人员、登 1 上海市锦天城律师事务所 关于杭州安旭生物科技股份有限公司 2024 年年度股东大会的 法律意见书 致:杭州安旭生物科技股份有限公司 上海市锦天城律师事务所(以下简称"本所")接受杭州安旭生物科技股份 有限公司(以下简称"公司")委托,就公司召开 2024年年 ...

Report Summary 1. Report Industry Investment Rating There is no information provided regarding the industry investment rating in the given content. 2. Report's Core View - The report focuses on the in - depth research of Anxu Bio, a biotech company in the medical device industry. It highlights the company's comprehensive strength, including its strong R & D capabilities, diverse product lines, and strategic layout for future development. Anxu Bio aims to become a leading enterprise in the international in - vitro diagnostic industry through continuous innovation and market expansion [23][24]. 3. Summary by Related Catalogs 3.1. Research Basic Situation - The research object is Anxu Bio, belonging to the medical device industry. The reception time was on May 20, 2025. The listed company's reception staff included the company's chairman and general manager Ling Shisheng, board secretary Han Jun, financial controller Kang Min, and independent director Zhang Guobiao [16]. 3.2. Detailed Research Institutions - The relevant personnel participated in the "2024 Annual Report and 2025 First - Quarter Performance Briefing" [19]. 3.3. Research Institution Proportion There is no specific information provided about the research institution proportion in the given text. 3.4. Main Content Data 3.4.1. Company Basic Situation Introduction - Anxu Bio was founded in 2008 and went public on the Science and Technology Innovation Board in November 2021. It is a high - tech biotech enterprise integrating R & D, production, and sales of in - vitro diagnostic reagents, POCT instruments, and biological raw materials. It has achieved an integrated industrial chain layout from upstream core biological raw materials to diagnostic reagents and instruments [23]. - The company has eight major fields of POCT reagents and related supporting instruments, covering drug testing, infectious disease testing, etc., and its products are sold in more than 150 countries and regions. It also actively strategically layouts in the pharmaceutical field, such as third - party medical testing laboratories, pet health management, and family health management [23][24]. - In the future, the company will continue to increase investment in R & D and production of biological raw materials, improve the performance of POCT reagents and instruments, and focus on both international and domestic markets to become a leading enterprise in the international in - vitro diagnostic industry [24]. 3.4.2. Q&A Session Main Content - **Financial Performance**: In 2024, the company's operating income was 540.6985 million yuan, net profit attributable to the parent company was 192.2953 million yuan, and net profit attributable to the parent company after deducting non - recurring gains and losses was 37.8979 million yuan. In the first quarter of 2025, the operating income was 115.2965 million yuan, net profit attributable to the parent company was 34.0296 million yuan, and net profit attributable to the parent company after deducting non - recurring gains and losses was 22.7603 million yuan [25]. - **R & D Breakthroughs and Advantages**: The company has built nine technology platforms, forming a trinity industrial chain layout of raw materials, reagents, and instruments. In 2024, it added 44 authorized patents (including 13 invention patents), with a total of 305 authorized patents, and added 606 international and domestic certifications, with a total of 1580 certifications, including EU CE and US FDA [25]. - **Business Expansion**: The company promotes the iteration of core products, builds a diversified product matrix, and explores performance growth potential in fields such as pet health management, family health management, and medical testing laboratories, advancing the Anxu Bio medical and health ecosystem strategy [26]. - **Future Profit Growth Drivers**: The company will focus on technological innovation, increase R & D investment, explore frontier technology fields, continue to expand overseas markets while increasing efforts in the domestic market, and consider expanding medical and health - related business through cooperation, investment, or mergers and acquisitions [26]. - **GluMate App**: With the rising global prevalence of chronic diseases, GluMate is launched to improve the health management of chronic disease patients. It aims to transform from single - detection to full - cycle service and build a chronic disease monitoring product system centered on GluMate, providing intelligent and personalized chronic disease management solutions [27]. - **2024 Dividend Policy**: In 2024, the company plans to distribute a cash dividend of 8 yuan per 10 shares (tax - included) to all shareholders, with a total cash dividend of 152.499366 million yuan (including the interim dividend), accounting for 79.30% of the net profit attributable to listed company shareholders in the 2024 consolidated statements [28]. - **Market Expansion Measures and Achievements**: The company adheres to the "international + domestic" dual - wheel drive strategy. Overseas, its products are sold in more than 150 countries and regions, and it participates in well - known exhibitions to enhance brand influence. Domestically, it has obtained new product registration certificates and promoted brand sales through online and offline channels. It has also established subsidiaries in Singapore, the United States, and Europe to optimize the global marketing network [28][29].

Core Viewpoint - The 2024 Annual General Meeting of Hangzhou Anxu Biotechnology Co., Ltd. will address various proposals including the work reports of the Board of Directors and Supervisors, the annual financial report, and profit distribution plans, reflecting the company's operational performance and governance structure [1][6][22]. Group 1: Meeting Procedures and Regulations - Shareholders must provide identification and authorization documents to attend the meeting, ensuring orderly conduct and protection of shareholder rights [2][4]. - The meeting will combine on-site and online voting, with specific time slots for each voting method [4][5]. - The agenda includes sign-in, introduction of attendees, reading of meeting rules, and sequential voting on proposals [5][6]. Group 2: Financial Performance - The company reported a net profit attributable to shareholders of 192.30 million yuan, a 35.85% increase year-on-year, while the net profit after deducting non-recurring items decreased by 27.6% to 37.90 million yuan [8][23]. - Total assets as of the end of 2024 were 5.77 billion yuan, a slight decrease of 0.35% compared to the previous year [23][24]. - The company achieved a revenue of approximately 540.70 million yuan, reflecting a growth of 7.42% from the previous year [24]. Group 3: Governance and Oversight - The Board of Directors and Supervisors have conducted their duties in accordance with relevant laws and regulations, ensuring compliance and protecting shareholder interests [17][22]. - The independent directors provided reports summarizing their activities and recommendations for the upcoming year, emphasizing their role in corporate governance [6][13]. - The Supervisory Board confirmed that the company operated within legal frameworks and that there were no violations or irregularities in financial reporting [20][22]. Group 4: Future Plans - The company aims to enhance its governance structure and internal controls, focusing on sustainable development and maximizing shareholder value [14][15]. - Plans for 2025 include advancing technological innovation, expanding product lines, and improving operational efficiency to strengthen market competitiveness [14][15].

杭州安旭生物科技股份有限公司 2024 年年度股东大会会议资料 杭 州 安 旭 生 物 科 技 股 份 有 限 公 司 2024 年年度股东大会会议资料 股票简称：安旭生物 2025 年 5 月 22 日 1 股票代码：688075 杭州安旭生物科技股份有限公司 2024 年年度股东大会会议资料 目 录 | 东 2024 | | | 年 | | | 年 | | | 度 | | 股 | | | | | 大 | | 会 | | | 须 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 知……………………………………………………………………………..………3 | | | | | | | | | | | | | | | | | | | | | | | | | 东 2024 | | | 年 | | | 年 | | | 度 | | 股 | | | | | 大 | | ...

民生证券股份有限公司 关于杭州安旭生物科技股份有限公司 首次公开发行股票并在科创板上市之保荐总结报告书 根据《证券发行上市保荐业务管理办法》、《上海证券交易所科创板股票 上市规则》、《上海证券交易所科创板上市公司自律监管指引第1号——规范 运作》等有关法律、法规的规定，民生证券股份有限公司（以下简称"民生证 券"或"保荐机构"）作为杭州安旭生物科技股份有限公司（以下简称"安 旭生物"或"公司"）首次公开发行股票并在科创板上市的保荐机构，负责安 旭生物上市后的持续督导工作，持续督导期间为2021年11月18日至2024年12 月31日。2024年12月31日，持续督导期已届满，民生证券根据《证券发行上 市保荐业务管理办法》《上海证券交易所科创板股票上市规则》等有关规定， 出具本保荐总结报告书。 一、 保荐机构及保荐代表人承诺 保荐总结报告书及其相关资料的内容不存在虚假记载、误导性陈述或重大 遗漏，保荐机构及保荐代表人对其真实性、准确性、完整性承担法律责任。 保荐机构及保荐代表人自愿接受中国证监会对保荐总结报告书相关事项进 行的任何质询与调查。 保荐机构及保荐代表人自愿接受中国证监会按照《证券发行上市保荐业务 管 ...